Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. - Wikidata - awgldk - TriplyDB

Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

http://www.wikidata.org/entity/Q53507722

about

Biomarkers and recent advances in the management and therapy of sickle cell disease Stroke in patients with sickle cell disease.Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1.Association of coagulation activation with clinical complications in sickle cell disease Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.Peroxisome proliferator-activated receptor-α-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1α Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells.MicroRNA 648 Targets ET-1 mRNA and is cotranscriptionally regulated with MICAL3 by PAX5.Sickle cell disease: a neglected chronic disease of increasing global health importance Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy.Sickle cell disease and venous thromboembolism.Vasculopathy and pulmonary hypertension in sickle cell disease.Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know A pilot study of subcutaneous decitabine in β-thalassemia intermedia Elevated hypercoagulability markers in hemoglobin SC disease.Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice Peroxisome proliferator-activated receptor-α-mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulates endothelin-1 and PAI-1 expression in sickle cell disease Hypercoagulability in congenital haemolytic anaemias Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease.Pathophysiology and treatment of pulmonary hypertension in sickle cell disease A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.Coagulation activation in sickle cell trait: an exploratory study Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

P2860

Q28082462-5D4C1D7C-0DBD-4165-A9E0-684E0C280542 Q30650303-5321A125-DB90-4CD5-8785-123FD1C0B46A Q30945205-D3FCEC9A-872A-4110-B8E4-C777BD273ED2 Q33690900-C3E71DAE-D269-4CF7-8AEC-82C5ECED49D8 Q33722654-DF7BD2B0-5315-4FE3-B31E-F3D9EC138421 Q33803027-B001BE21-E1C0-441A-9D3C-C4CA29C2D656 Q33883207-5ACDB415-DE06-4EEB-BFE5-CB6E67ADB38B Q33899415-315CC976-1E93-4ADB-B552-CD8EAEA90BB4 Q33997180-19A10A2B-DB26-4AB2-9ACF-757151CBB70F Q34073285-F1EB1916-4439-4334-B01A-541F6582651A Q34130633-19BAD7EA-4A69-4C17-BDF5-7809C90B3ECA Q34466198-8450F631-B5CC-4F57-8019-6D3A408F23BE Q34718108-84A03220-FAB3-447F-A2CC-9910059DEE9D Q34774521-6BFB62F4-7BA4-441C-B697-698DBCDC7DEF Q34806514-0310F202-4D88-4778-96A4-23145DF983DB Q34846466-3327945B-48EF-4907-AB5C-1CF9657DBA36 Q34852524-B248226C-3090-47E6-92A4-F6F89E2DD7F6 Q34898802-891417E1-72EA-4B7A-9F77-42E306F4DC74 Q34992760-863A43C4-DA98-4627-ACC4-F29000A23251 Q35036717-309895C4-5E73-46AB-9938-496DC44A0465 Q35039996-636018C9-AA72-452D-96E6-F16A2C5A3F66 Q35086394-C080939A-5B9D-4275-A4B9-D772DC9A2E02 Q35105431-BD16948B-6794-4F61-9144-2D894C8673ED Q35212344-9DC9406E-C6CC-4D68-B10C-7A7245F040B9 Q35236050-7B326000-1735-45A9-A4FB-796993E6AC84 Q35590733-78C897CF-4DE3-49E6-940A-70C8162C4BF9 Q35754765-372C317B-6D81-4B02-8873-3020D1CD8DE6 Q36106316-855C14D6-5FF9-4CD1-B32D-85C857089BD0 Q36143261-73B2649C-3074-4627-B087-B77879AC7A49 Q36353647-4C81CCE1-5472-4569-AEED-10D0BF37E535 Q36393525-0C302A9A-46C3-4B45-98FB-605C3E80CC62 Q36470075-54CF3F27-574C-4A18-A760-5DBF751DC198 Q36596861-DA9DBAAB-492B-4D5E-9DFB-A4F3FE2F20E9 Q36649213-4F51BF16-A771-4401-821C-22528BAC65B4 Q36657988-8F0D4EE2-F98E-4EA7-98C8-63B81CCCB7BE Q36661960-B3952B75-A736-4CC5-A62B-C8B796EB861A Q36768295-9611055E-D847-404F-926B-DD07D9910A9A Q36862364-345E953A-4DF6-4FF6-900A-136105045A3B Q37033939-74A8C355-6CCB-4DA9-9726-14FCB7791267 Q37565002-AD00620B-B66A-47EC-B75B-94AB5972626E

P2860

Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

http://www.wikidata.org/entity/Q53507722

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Coagulation activation and inf ...... ciated pulmonary hypertension.

@en

Coagulation activation and inf ...... ciated pulmonary hypertension.

@nl

type

label

Coagulation activation and inf ...... ciated pulmonary hypertension.

@en

Coagulation activation and inf ...... ciated pulmonary hypertension.

@nl

prefLabel

Coagulation activation and inf ...... ciated pulmonary hypertension.

@en

Coagulation activation and inf ...... ciated pulmonary hypertension.

@nl

P1433

Q53507722-D889204C-B9F8-4973-AB07-42BF4AB5CFDC

P1476

Q53507722-46C4C663-13D1-4774-BCDC-E768136B0A44

P2093

Q53507722-094E696F-0E9B-4995-8913-7A710B8A15A2

Q53507722-142FE934-8858-4401-B276-0C01A5367FE7

Q53507722-69597169-1D58-4FDC-AC61-C64AF152E89D

Q53507722-6CA2A170-0ED5-4843-8472-45C345BB907B

Q53507722-7FC32515-6CB4-496F-8C1A-A75D651E55A9

Q53507722-F07E4D21-F4A9-41AF-A2D1-383541929C84

Q53507722-F7B4636F-7621-4679-B7F2-AAD4D5CE929A

Q53507722-FD319F34-2C40-4189-B509-DAE3B76EB1FF

Q53507722-FE20BB4F-73EC-43EB-8097-45B64C705867

P304

Q53507722-D04607E1-6F63-4F45-9E11-58844B5F620F

P31

Q53507722-6631C101-C625-42EB-9DEE-668AA47B4106

P356

Q53507722-A783B0F5-58E0-4E6B-9CBE-7AF5CCEA090D

P433

Q53507722-DD67C077-8CCB-4ECE-9E4F-A2629CB5A20A

P478

Q53507722-C247E9E8-488A-42D8-B61C-2CCA73E47CAB

P50

Q53507722-642198EA-B91B-4F60-B80B-1328E72D6B44

P577

Q53507722-E1D4769C-8EF2-46FB-9C0D-C35D381F8BE0

P5875

Q53507722-2FB0A341-4141-43C9-9A01-34990E536DB2

P698

Q53507722-5C1EDA2B-5F7D-4FD6-B40F-1C202E9B6A04

P356

P1433

P1476

Coagulation activation and inf ...... ciated pulmonary hypertension.

@en

P2093

Alan Hinderliter

http://www.w3.org/2001/XMLSchema#string

Cathy Sohier

http://www.w3.org/2001/XMLSchema#string

Cheryl A Hillery

http://www.w3.org/2001/XMLSchema#string

Dell Strayhorn

http://www.w3.org/2001/XMLSchema#string

Eugene P Orringer

http://www.w3.org/2001/XMLSchema#string

Herbert C Whinna

http://www.w3.org/2001/XMLSchema#string

Kenneth I Ataga

http://www.w3.org/2001/XMLSchema#string

Leslie V Parise

http://www.w3.org/2001/XMLSchema#string

Susan Jones

http://www.w3.org/2001/XMLSchema#string

P304

20-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.11763

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Charity G Moore

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5682519

http://www.w3.org/2001/XMLSchema#string

P698

18166781

http://www.w3.org/2001/XMLSchema#string